Mechanism and Innovation in CAR T Cell Therapy
CAR T cell therapy relies on a multi-step process that transforms a patient’s immune system into a targeted cancer-fighting machine. Initially, T cells are harvested from the patient and then genetically modified in a lab to express CARs, which recognize tumor-specific antigens. Once reintroduced, these cells seek out and destroy cancer cells with precision.
Innovation has led to the development of next-generation CAR T cells with enhanced persistence, reduced toxicity, and improved tumor infiltration. Scientists are exploring “armored” CAR T cells, which secrete supportive cytokines to enhance immune response, and dual-targeting CARs, capable of attacking multiple cancer antigens simultaneously.
These advancements aim to increase the efficacy of therapy against solid tumors, a challenge that earlier CAR T therapies struggled with. With ongoing clinical studies, CAR T cell therapy is poised to expand beyond hematological cancers, offering potential solutions for a wider range of malignancies.